MACS
^®
GMP Recombinant Human TPO

Name: MACS® GMP Recombinant Human TPO
Availability: InStock

MACS
^®
GMP Recombinant Human TPO

Thrombopoietin (TPO), also termed megakaryocyte growth and development factor (MGDF), is a glycoprotein hormone and the major stimulator of megakaryopoiesis and platelet production. It promotes the proliferation of hematopoietic stem cells, primitive progenitors, megakaryocytes, and platelets.

MACS GMP Recombinant Human TPO is designed for

ex vivo

cell culture processing. No animal- or human-derived materials were used for the manufacture of this product. The product is lyophilized without carrier protein or preservatives.

Product data and images for MACS
^®
GMP Recombinant Human TPO

Figures

Figure 1

Mass spectrometry analysis (ESI-MS) of MACS GMP Recombinant Human TPO. The first RP-HPLC peak corresponds to the calculated molecular mass of 18804 Da with N-terminal methionine.

Figure 1

Mass spectrometry analysis (ESI-MS) of MACS GMP Recombinant Human TPO. The first RP-HPLC peak corresponds to the calculated molecular mass of 18804 Da with N-terminal methionine.

Figure 2

Mass spectrometry analysis (ESI-MS) of MACS GMP Recombinant Human TPO. The second RP-HPLC peak corresponds to the calculated molecular mass of 18832 Da with N-terminal formyl-methionine.

Figure 2

Mass spectrometry analysis (ESI-MS) of MACS GMP Recombinant Human TPO. The second RP-HPLC peak corresponds to the calculated molecular mass of 18832 Da with N-terminal formyl-methionine.

Figure 3

**MACS GMP Recombinant Human TPO biological activity.**
Activity of Human TPO, GMP grade, (blue bar) was compared to another commercially available product (black bar).

Figure 3

MACS GMP Recombinant Human TPO biological activity.

Activity of Human TPO, GMP grade, (blue bar) was compared to another commercially available product (black bar).

Specifications for MACS
^®
GMP Recombinant Human TPO

Overview

Thrombopoietin (TPO), also termed megakaryocyte growth and development factor (MGDF), is a glycoprotein hormone and the major stimulator of megakaryopoiesis and platelet production. It promotes the proliferation of hematopoietic stem cells, primitive progenitors, megakaryocytes, and platelets.

MACS GMP Recombinant Human TPO is designed for

ex vivo

cell culture processing. No animal- or human-derived materials were used for the manufacture of this product. The product is lyophilized without carrier protein or preservatives.

Detailed product information

Background information

TPO is expressed in liver, kidney, spleen, lung, bone marrow, and brain. The TPO receptor is a product of the proto-oncogene

c-mpl

and displays homology with type I cytokine receptor superfamily members. The receptor is present mainly on hematopoietic stem cells, megakaryocytic progenitors, megakaryocytes, and platelets.

Applications

MACS GMP Recombinant Human TPO can be used for a variety of applications, including the expansion

²^,3

and the viral transduction

⁴^,5

of hematopoietic stem and progenitor cells derived from bone marrow, peripheral blood cells, and cord blood, or the

in vitro

differentiation of megakaryocytes

⁶

.

Biological activity

The specific activity is determined by proliferation assay according to Page
et al.¹
using M07e cells. The proliferation assay was calibrated with the Non WHO Reference Material for human TPO (NIBSC code 03/124) provided by the National Institute for Biological Standards and Control.
Minimal specific activity: ≥ ≥ 1×
10
⁷
U/mg

Quality statement

MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.

Disclaimer

MACS GMP Products are for

ex vivo

cell processing only, and are not intended for human

in vivo

applications. For regulatory status in the USA, please contact your local representative.

Resources for MACS
^®
GMP Recombinant Human TPO

Documents and Protocols

Brochures/posters

Generation of gene-engineered hematopoietic stem cells - CliniMACS Prodigy® Hematopoietic Stem Cell Engineering System

Brochures/posters

MACS® GMP Cytokines - Culture is key

Brochures/posters

CliniMACS Prodigy® HSC Engineering process

Scientific posters

Automation of hematopoietic stem cell transduction: Results of a head-to-head comparison between a manual and an automated procedure

App notes/customer reports

The reliability of stated cytokine activities

App notes/customer reports

Your guide to side-by-side cytokine comparison

App notes/customer reports

MACS® GMP Cytokines - Cytokine stability studies

App notes/customer reports

Recombinant cytokines and their biological activity

App notes/customer reports

Bioassays and calibration reagents used for activity calibration of MACS Cytokines

Certificates

Please follow this

link

to search for Product Quality Certificates (PQC) by lot number.

References for MACS
^®
GMP Recombinant Human TPO

Publications

Page, L. A. et al. (1996) A sensitive human cell line based bioassay for megakaryocyte growth and development factor or thrombopoietin. Cytokine 8(1): 66-69
Kaushansky, K. and Drachman, J. G. (2002) The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene 21(21): 3359-3367
Petzer, A. L. et al. (1996)
Differential cytokine effects on primitive (CD34
⁺
CD38
^-
) human hematopoietic cells: novel responses to Flt3-ligand and thrombopoietin.
J. Exp. Med. 183(6): 2551-2558
Kiem, H. P. et al. (1998) Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. Blood 92(6): 1878-1886
Uchida, N. et al. (2011)
Optimal conditions for lentiviral transduction of engrafting human CD34
⁺
cells.
Gene Ther. 18(11): 1078-1086
Bruno, S. et al. (2003)
In vitro
and
in vivo
megakaryocyte differentiation of fresh and
ex-vivo
expanded cord blood cells: rapid and transient megakaryocyte reconstitution.
Haematologica 88(4): 379-387

Data and images